Coryell W, Endicott J, Maser J D, Mueller T, Lavori P, Keller M
National Institute of Mental Health Collaborative Program, Psychobiology of Depression--Clinical Studies, Department of Psychiatry, Iowa City, IA 52242, USA.
J Affect Disord. 1995 Mar 14;33(3):201-6. doi: 10.1016/0165-0327(94)00091-m.
These analyses used a high-intensity follow-up of of patients with bipolar affective disorder to describe the immediate and long-term risks for recurrence and the importance of sustained recovery to those risks. At the baseline evaluation, all patients were in episodes of Research Diagnostic Criteria major depressive disorder, mania or schizoaffective disorder (excluding the mainly schizophrenic subtype); those who were depressed at intake had a history of mania or schizoaffective mania. Raters re-evaluated these patients at 6-month intervals for 5 years and annually for the remainder of a 10-year follow-up. The following report describes relapse risks for the 186 patients observed to recover from their index episodes. Survival analyses quantified the likelihood of relapse over time, beginning after symptom-free periods of 4 months and 1, 2 and 3 years. Further survival analyses used treatment status as a censoring variable to estimate the eventual likelihood of recurrence among those who reported sustained compliance with lithium prophylaxis; the prophylaxis group remained under observation until they relapsed, were lost to follow-up or ceased taking lithium. Progressively longer symptom-free periods were clearly associated with lower relapse risks over the subsequent 4 years. Thereafter, however, this effect dissipitated. 7 years after recovery, the cumulative likelihood of recurrence was four in five for all bipolar patients and two in three for those whose index episode had been followed by at least 3 years without symptoms. Even with sustained lithium prophylaxis, the likelihood of at least one recurrence exceeded 70% within 5 years of recovery.(ABSTRACT TRUNCATED AT 250 WORDS)
这些分析通过对双相情感障碍患者进行高强度随访,来描述复发的近期和长期风险,以及持续康复对这些风险的重要性。在基线评估时,所有患者均处于研究诊断标准中的重度抑郁症、躁狂症或分裂情感性障碍发作期(不包括主要为精神分裂症的亚型);入院时抑郁的患者有躁狂或分裂情感性躁狂病史。评估人员在5年中每6个月对这些患者重新评估一次,在10年随访的剩余时间里每年评估一次。以下报告描述了从首次发作中康复的186例患者的复发风险。生存分析量化了从4个月、1年、2年和3年无症状期后开始随时间推移的复发可能性。进一步的生存分析将治疗状态作为一个审查变量,以估计那些报告持续遵医嘱服用锂盐预防的患者最终复发的可能性;预防组一直接受观察,直到他们复发、失访或停止服用锂盐。在随后的4年中,无症状期越长,复发风险明显越低。然而,此后这种效果消失。康复7年后,所有双相情感障碍患者复发的累积可能性为五分之四,首次发作后至少3年无症状的患者复发的累积可能性为三分之二。即使持续服用锂盐预防,康复后5年内至少复发一次的可能性超过70%。(摘要截短为250字)